摘要
本文报告的流程为:被筛选的药物用正常普通小鼠测定其LD_(50),而后取其1/10量注射于荷瘤裸小鼠腹腔,3天后再腹腔注射~3H-TdR30μci/鼠,18小时后取移植瘤、股骨和小肠制成匀浆测CPM值。根据被测组织中掺入的~3H-TdR量来评价被筛选药物的抗癌活性和毒性副作用。
Study on the anticancer drug screening program with human tumor xe-nografted in nude mice was reported. The screening drugs were tested for the LD50 in normal mice. The trmor bearing nude mice were firstly injected with 1/10 of the LD50 IP, three days later injected with 3H-TdR at a dose 30μci per mouse. 18 hours after the injection of isotops the mice were killed and homogenates were prepared from xenografted tumor, femur bone and small intestine. Their CPM's were then measured. The anticancer activity and side effects of each tested drug were evaluated by comparing the incorporated 3H-TdR in tumor versus normal tissue.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1991年第3期187-189,共3页
Chinese Journal of Cancer
基金
江苏省自然科学基金
关键词
药物筛选
同位素掺入
人癌移植
Drugs Screening, Isotopt Incorporated Human cancer transplamted
Nude mice
